Abstract:e21024 Background: Though the gut microbiome has been associated with immunotherapy (ICI) efficacy in certain cancers, similar correlations between microbiomes at other body sites with treatment response and immune related adverse events (irAEs) in lung cancer (LC) patients receiving ICIs have not been made. We designed a prospective cohort study conducted from 2018-2020 at a single-center academic institution to assess for correlations between the microbiome in various body sites with treatment response and development of irAEs in LC patients treated with ICIs. Methods: Patients with histopathologically confirmed, unresectable/advanced/metastatic LC planned to undergo ICI-based therapy were enrolled between September 2018 and June 2019. Patients must have had measurable disease, ECOG 0-2, and good organ function to be included. Data was collected for analysis from January 2019 to October 2020. Nasal, buccal and gut microbiome samples were obtained prior to ICI initiation, at development of irAEs, improvement of irAEs to grade 1 or less, and at disease progression. 16S rRNA sequenced data was mapped to the SILVA 13.2 database; operational taxonomic unit clusters were analyzed using MicrobiomeAnalyst and METAGENassist. Results: 37 patients were enrolled, and 34 patients were evaluable for this report. 32 healthy controls (HC) from the same geographic region were included to compare baseline gut microbiota. Compared to HC, LC gut microbiota exhibited significantly lower α-diversity. The gut microbiome of patients who did not suffer irAEs were found to have relative enrichment of Bifidobacterium ( p = 0.001) and Desulfovibrio ( p = 0.0002). Responders to combined chemoimmunotherapy exhibited increased Clostridiales ( p = 0.018) but reduced Rikenellaceae ( p = 0.016). In responders to chemoimmunotherapy we also observed enrichment of Finegoldia in nasal microbiome, and increased Megasphaera but reduced Actinobacillus in buccal samples. Longitudinal samples exhibited a trend of α-diversity and certain microbial changes during the development and resolution of irAEs. Conclusions: This pilot study identified significant differences in the gut microbiome between HC and LC patients, and correlates specific bacterial genera to ICI response and irAEs in LC. In addition, it suggests potential predictive utility in nasal and buccal microbiomes, warranting further validation with a larger cohort and mechanistic dissection using preclinical models. Clinical trial information: NCT03688347.

A Theoretical Foundation for the Stein-Winter "Probability Hypothesis Density (PHD)" Multitarget Tracking Approach

Plasma Concentrations of Second-Line Antituberculosis Drugs in Relation to Minimum Inhibitory Concentrations in Multidrug-Resistant Tuberculosis Patients in China: a Study Protocol of a Prospective Observational Cohort Study.

Prospective Correlation Between the Patient Microbiome with Response to and Development of Immune-Mediated Adverse Effects to Immunotherapy in Lung Cancer.

Drug Exposure and Susceptibility of Second-Line Drugs Correlate with Treatment Response in Patients with Multidrug-Resistant Tuberculosis: a Multicentre Prospective Cohort Study in China.

Relationship between clarithromycin MICs and treatment responses in Mycobacterium avium complex pulmonary disease

The role of treatment regimen and duration in treating patients with Mycobacterium avium complex lung disease: a real-world experience and case-control study

Short-course Regimen for Subsequent Treatment of Pulmonary Tuberculosis: A Prospective, Randomized, Controlled Multicenter Clinical Trial in China.

Effect of multidrug therapy on the prognosis of Mycobacterium avium complex pulmonary disease

Space-time evolution of nuclear reactions probed by two-proton intensity interferometry.

Clinical course and risk factors of mortality in Mycobacterium avium complex lung disease without initial treatment

In Vitro Assessment of 17 Antimicrobial Agents Against Clinical Mycobacterium Avium Complex Isolates

Variables associated with antibiotic treatment tolerance in patients with Mycobacterium avium complex pulmonary disease

Longitudinal Profiling of Gut Microbiome among Tuberculosis Patients under Anti-Tuberculosis Treatment in China: Protocol of a Prospective Cohort Study

Assessment of a wrist-worn device in the detection of obstructive sleep apnea.

[Bilateral anterolateral approach in primary tumors of the cervical vertebrae].

In vitro estradiol uptake by the pituitary, median eminence and hippocampus in rats.

Efficacy and safety of modified Bushen Yiqi formulas (MBYF) as an add-on to formoterol and budesonide in the management of COPD: study protocol for a multicentre, double-blind, placebo-controlled, parallel-group, randomized clinical trial: FB-MBYF Trial

Second-line anti-tuberculosis drug exposure thresholds predictive of adverse events in multidrug-resistant tuberculosis treatment

Clinical outcomes of lung transplant recipients with pre‐transplant Mycobacterium avium complex infection

Drug exposure and treatment outcomes in patients with multidrug resistant tuberculosis and diabetes mellitus: A multicenter prospective cohort study from China

Selecting an appropriate all-oral short-course regimen for patients with multidrug-resistant or pre-extensive drug-resistant tuberculosis in China: A multicenter prospective cohort study